Results 241 to 250 of about 1,282,511 (265)

Avapritinib for Advanced Systemic Mastocytosis.

Blood, 2022
Avapritinib, a selective inhibitor of KIT D816V, was approved by the Food and Drug Administration in 2021 for treatment of advanced systemic mastocytosis (AdvSM), and by the European Medicines Agency in 2022 for AdvSM patients after prior systemic ...
J. Gotlib, A. Reiter, D. DeAngelo
semanticscholar   +1 more source

Avapritinib: an emerging new therapy for systemic mastocytosis.

Expert Review of Hematology, 2021
P. Bose, S. Verstovsek
semanticscholar   +1 more source

Osteoporosis Caused by Systemic Mastocytosis: Prevalence in a Cohort of 8392 Patients with Osteoporosis

Calcified Tissue International, 2021
M. Gehlen, N. Schmidt, M. Pfeifer, Subathira Balasingam, M. Schwarz-Eywill, A. Maier, M. Werner, H. Siggelkow   +7 more
semanticscholar   +1 more source

Disease correlates and clinical relevance of Hereditary Alpha-Tryptasemia in patients with Systemic Mastocytosis.

Journal of Allergy and Clinical Immunology, 2022
Benedetta Sordi, F. Vanderwert, F. Crupi, F. Gesullo, R. Zanotti, P. Bonadonna, L. Crosera, C. Elena, Nicolas Fiorelli, Jacqueline Ferrari, F. Grifoni, M. Sciumè, R. Parente, M. Triggiani, B. Palterer, Valentina Mecheri, F. Almerigogna, R. Santi, L. Di Medio, M. Brandi, M. Iorno, Isabella Ciardetti, S. Bencini, F. Annunziato, C. Mannarelli, L. Pieri, P. Guglielmelli, F. Mannelli, A. Vannucchi   +28 more
semanticscholar   +1 more source

Tyrosine kinase inhibitors for the treatment of indolent systemic mastocytosis: are we there yet?

Journal of Allergy and Clinical Immunology, 2022
C. Akin, M. Arock, P. Valent
semanticscholar   +1 more source

Allogeneic haematopoietic cell transplantation for advanced systemic mastocytosis: Best practice recommendations on behalf of the EBMT Practice Harmonisation and Guidelines Committee

Leukemia
D. Mclornan, T. Czerw, G. Damaj, M. Ethell, C. Gurnari, J. Hernández-Boluda, N. Polverelli, J. Schwaab, Katja Sockel, Greco Raffaella, Francesco Onida, Isabel Sanchez-Ortega, G. Battipaglia, Chiara Elena, J. Gotlib, A. Reiter, J. Rossignol, Celalettin Ustun, P. Valent, I. Yakoub-Agha, D. Radia   +20 more
semanticscholar   +1 more source

Proposed global prognostic score for systemic mastocytosis: a retrospective prognostic modelling study.

The Lancet Haematology, 2021
J. Muñoz-González, I. Alvarez-Twose, M. Jara-Acevedo, R. Zanotti, C. Perkins, M. Jawhar, W. Sperr, Khalid Shoumariyeh, J. Schwaab, Georg Greiner, Ana Henriques, C. Caldas, C. Fernández-Giménez, L. Sánchez-Muñoz, A. Mayado, A. Pérez-Pons, A. Schmitt-Graeff, J. Duyster, I. Tanasi, Francesco Olivieri, E. Mora-Casterá, I. Luna, L. Senent, M. Bañas, Amanda Núñez-García, M. Jurado-Chacón, G. Martín-Sánchez, E. Colado, B. Xicoy, Georgina Gener-Ricós, J. Gotlib, P. Bonadonna, A. Reiter, P. Valent, A. García-Montero, A. Órfão   +35 more
semanticscholar   +1 more source

Mastocytosis-derived extracellular vesicles deliver miR-23a and miR-30a into pre-osteoblasts and prevent osteoblastogenesis and bone formation

Nature Communications, 2021
Do-Kyun Kim, Geethani Bandara, Young-Eun Cho   +2 more
exaly  

Avapritinib in the Treatment of Systemic Mastocytosis: an Update

Current Hematologic Malignancy Reports, 2021
Samantha Below, L. Michaelis
semanticscholar   +1 more source

Advances in Understanding and Management of Myeloproliferative Neoplasms

Ca-A Cancer Journal for Clinicians, 2009
Paola Guglielmelli
exaly